Evidence map›Paper›PMID 39478667›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2024

Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC.

Petr Peichl, Antoni Bayes-Genis, Thomas Deneke, Ovidiu Chioncel, Marta deRiva, Maria Generosa Crespo-Leiro, Antonio Frontera, Finn Gustafsson, Raphaël P Martins, Matteo Pagnesi and 14 more

Erratum issuedAbstract readConsensus Statement
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Ventricular arrhythmias following left ventricular assist device implantation: a systematic review and meta-analysis of incidence and clinical impact.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Pooled it
  3. Article
  4. Impacts of Hemodynamic Support on Ventricular Arrhythmia Ablation.Journal of cardiovascular electrophysiology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Prediction of late ventricular arrhythmias in patients with left ventricular assist device: insights from the VT-LVAD consortium.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED registry).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Petr PeichlDepartment of Cardiology, IKEM, Vídeňská 1958/9, Prague, Czech Republic.ORCID 0000-0002-5625-0071
Antoni Bayes-GenisHeart Institute at Hospital Universitari Germans Trias i Pujol, CIBERCV, Badalona, Spain.ORCID 0000-0002-3044-197X
Thomas DenekeClinic for Arrhythmology, Klinikum Nuernberg Süd, University Hospital of the Paracelsus Medical University, Nuernberg, Germany.ORCID 0000-0003-1379-1684
Ovidiu ChioncelInstitute of Emergency for Cardiovascular Diseases, 'C.C.Iliescu'  Bucharest, Romania.ORCID 0000-0002-3197-3628
Marta deRivaLeiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5878-6750
Maria Generosa Crespo-LeiroComplexo Hospitalario Universitario A Coruña (CHUAC)-CIBERCV, Instituto de Investigación Biomedica A Coruña (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain.ORCID 0000-0002-3085-167X
Antonio FronteraDepartment of Cardiac Electrophysiology, Great Metropolitan Hospital Niguarda, Milan, Italy.ORCID 0000-0002-0372-4480
Finn GustafssonDepartment of Cardiology, Rigshospitalet, Denmark.ORCID 0000-0003-2144-341X
Raphaël P MartinsDepartment of Cardiology, University Hospital of Rennes, Rennes, France.ORCID 0000-0001-5716-6712
Matteo PagnesiDepartment of Medical and Surgical Specialties, Radiological sciences and Public Health, Institute of Cardiology, ASST Spedali Civili, University of Brescia, Brescia, Italy.ORCID 0000-0002-9298-7871
Philippe MauryDepartment of Cardiology, Rangueil Hospital of Toulouse, Toulouse, France.ORCID 0000-0002-4800-1841
Mark C PetrieSchool of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6333-9496
Frederic SacherCardiac Arrhythmia Department, Univ. Bordeaux, CHU de Bordeaux, INSERM, CRCTB, U 1045, IHU Liryc, Bordeaux, France.ORCID 0000-0001-8348-9320
Offer AmirHeart Center, Hadassah Medical Center and Hebrew University, Jerusalem, Israel.ORCID 0000-0002-5624-2450
Luigi Di BiaseMontefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Isabel DeisenhoferDepartment of Electrophysiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.
Alessio GasparettiSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Mélèze HociniHôpital cardiologique du Haut Lévêque, Cardiology-Cardiac Electrophysiology Department, Pessac, France and IHU Liryc-L'Institut des maladies du rythme cardiaque, Site Hôpital Xavier Arnozan, Pessac, France.
Francisco Moscoso CostaDepartment of Cardiology, Hospital de Santa Cruz, Carnaxide, Lisbon, Portugal.
Brenda MouraArmed Forces Hospital, Porto, Portugal.
Hadi SkouriSchool of Medicine, Balamand University, Beirut-Lebanon, Abu Dhabi, UAE.
Carlo Gabriele TocchettiInternal Medicine Unit for Cancer Patients, Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center for Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, NA, Italy.
Maurizio VolterraniCardiopulmonary Department, San Raffaele Open University of Rome, IRCCS San Raffaele Roma, Roma, Italy.
Reza WakiliDepartment of Cardiology and Vascular Medicine, University Hospital Frankfurt, Goethe-University Frankfurt, ZIM-Med. Klinik 3-Kardiologie, Angiologie, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20-50% at one year after LVAD implantation. Arrhythmias predispose these patients to additional risk and are associated with considerable morbidity from recurrent implantable cardioverter-defibrillator shocks, progressive failure of the unsupported right ventricle, and herald an increased risk of mortality. Management of patients with arrhythmias and LVAD differs in many aspects from the general population heart failure patients. These include ruling out the reversible causes of arrhythmias that in LVAD patients may include mechanical irritation from the inflow cannula and suction events. For patients with symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant. There are specific technical and procedural challenges perceived to be unique to LVAD-related ventricular tachycardia (VT) ablation such as vascular and LV access, signal filtering, catheter manoeuvrability within decompressed chambers, and electroanatomic mapping system interference. In some patients, the arrhythmogenic substrate might not be readily accessible by catheter ablation after LVAD implantation. In this regard, the peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future VT recurrences. This document aims to address specific aspects of the management of arrhythmias in LVAD patients focusing on anti-arrhythmic drug therapy and ablations.

Indexed as

Anti-Arrhythmia AgentsArrhythmias, CardiacCatheter AblationHeart-Assist DevicesHeart FailureEuropeHumansRisk FactorsTachycardia, VentricularTreatment OutcomeVentricular Function, LeftAnti-Arrhythmia AgentsAtrial fibrillationCatheter ablationHeart failureLeft ventricular assist deviceVentricular arrhythmia

Identifiers

PMID39478667
PMCPMC11580222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.